BiotechTube

MEDI0457 + Durvalumab

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Conditions

HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma

Trial Timeline

Sep 17, 2019 → Mar 25, 2021

NCT ID
NCT04001413

About MEDI0457 + Durvalumab

MEDI0457 + Durvalumab is a phase 2 stage product being developed by AstraZeneca for HPV Positive Oropharyngeal Squamous Cell Carcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04001413. Target conditions include HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma.

What happened to similar drugs?

9 of 20 similar drugs in HPV Positive Oropharyngeal Squamous Cell Carcinoma were approved

Approved (9) Terminated (2) Active (10)
✅Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
✅GefitinibAstraZenecaApproved
✅ceritinibNovartisApproved
✅NilotinibNovartisApproved
✅AsciminibNovartisApproved
✅RAD001 + ExemestaneNovartisApproved
✅Trastuzumab emtansineRocheApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04001413Phase 2Withdrawn

Competing Products

20 competing products in HPV Positive Oropharyngeal Squamous Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
CT-0508 + PembrolizumabCarisma TherapeuticsPhase 1
23
CT-0525Carisma TherapeuticsPhase 1
23
TrastuzumabCelltrionPhase 3
40
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
31
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
YH32367YuhanPhase 1/2
39
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
26
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
33
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3
44
Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing MouthwashDaiichi SankyoPhase 1
33
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
35
ASP0113 + PlaceboAstellas PharmaPhase 3
40
IMAB362 + Zoledronic acid + Interleukin-2 (1 million IU) + Interleukin-2 (3 million IU)Astellas PharmaPhase 1
29
EnzalutamideAstellas PharmaPhase 2
35
ASP1893Astellas PharmaPhase 1
21